Akoya Biosciences announced that researchers from Akoya Biosciences and The University of Queensland’s Frazer Institute have comprehensively mapped the spatial proteome of head and neck squamous cell carcinoma using ultrahigh-plex spatial phenotyping. Spatial phenotyping consists of whole-slide imaging of tissue sections at single-cell resolution to visualize and quantitate biomarker expression and reveal how cells interact and organize across the entire tissue landscape. The study, published in GEN Biotechnology in an article titled “Mapping the Spatial Proteome of Head and Neck Tumors: Key Immune Mediators and Metabolic Determinants in the Tumor Microenvironment” identified a high degree of intra- and inter-tumoral heterogeneity intrinsic to head and neck cancers and advances the understanding of the mechanistic basis of variable clinical responses. The study analyzed head and neck cancer tissues from a patient with varying responses to immune checkpoint inhibitor therapy. The analysis was conducted using a panel of 100+ biomarkers to measure key cancer hallmarks of tumor and immune biology with Akoya’s PhenoCycler-Fusion system. The PhenoCycler-Fusion is the fastest spatial biology solution available which enables rapid imaging of whole slides at single-cell resolution. A pivotal discovery in the study highlighted the divergent enrichment of functionally specialized immune cell subsets, as well as distinct metabolic and stress signatures organized within specific spatial domains in the tumor. This overarching observation in the paper underscored the existence of heterogeneous niches and competitive microenvironments, potentially serving as defining factors for clinical response and resistance
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on AKYA:
- Akoya Biosciences Announces Peer-Reviewed Publication Using Ultrahigh-Plex Spatial Phenotyping of Head and Neck Cancer to Identify Distinct Immune and Metabolic Signatures
- Akoya Biosciences price target lowered to $11 from $14 at Piper Sandler
- Akoya to Report Third Quarter 2023 Financial Results on November 8th, 2023
- Akoya Biosciences participates in a conference call with JPMorgan
- Akoya Biosciences Sets a New Standard for Scaling Spatial Biology with the Launch of 2.0 Platforms